Although less successful than anti-TNF therapies in rheumatoid arthritis (RA), there appears to be considerable benefit in the management of Juvenile arthritis (Still's disease), and it is the treatment of choice in the rare autoinflammatory illnesses typified by Muckle-Wells syndrome. The gene discussed is TNF; the disease is rheumatoid arthritis.